KaydedilenlerDerginizi ekleyin

Dergiler / Journal of Medicine and Palliative Care / 2026 / Volume: 7 Issue: 5

Global research trends in biologic therapy for hidradenitis suppurativa: a bibliometric analysis

Esranur Ünal(UFUK UNIVERSITY, SCHOOL OF MEDICINE)0000-0002-8309-6452
Muhammed Burak Yücel(Memorial Kayseri Hastanesi)0000-0003-0130-8229
Sayfa
—
Yayın Tarihi
2026-10-25
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

This bibliometric analysis provides an overview of publication trends, influential contributors, and emerging research directions.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Aims: Research on biologic therapy for hidradenitis suppurativa (HS) has expanded considerably, yet comprehensive bibliometric evaluations remain limited.
📊
Temel Bulgular & Veri:English-language articles indexed in the Science Citation Index Expanded and published between 2016 and 2025 were included.
💡
Sonuç & Katkı:This bibliometric analysis provides an overview of publication trends, influential contributors, and emerging research directions.
🔬Tür:Research Article
📍Kapsam:2016 Verileri
⚙️Değişkenler:Hidradenitis suppurativa · biologic therapy · bibliometric analysis

Abstract

Aims: Research on biologic therapy for hidradenitis suppurativa (HS) has expanded considerably, yet comprehensive bibliometric evaluations remain limited. This study aimed to analyze the global scientific landscape of biologic therapy for HS by evaluating publication trends, influential journals, authors, countries, collaboration networks, and research hotspots. Methods: A bibliometric analysis was performed using the Web of Science Core Collection database. English-language articles indexed in the Science Citation Index Expanded and published between 2016 and 2025 were included. Following manual screening, 99 studies were analyzed. Publication, citation, source, country, and three-field plot analyses were performed using Biblioshiny, whereas author and country collaboration, keyword co-occurrence, and reference co-citation network analyses were performed using VOSviewer. Results: A total of 99 original articles were analyzed. Scientific production peaked in 2025, whereas publications from 2016 had the highest average citations per year. British Journal of Dermatology was the most productive journal. The most globally cited article was the phase III adalimumab trial by Kimball et al. The United States showed the highest author-affiliation frequency and the strongest international collaboration. Prens EP., Jemec GBE., and Giamarellos-Bourboulis EJ. showed the strongest collaborations, whereas Jemec GBE. received the most citations. Keyword analysis identified HS, adalimumab, biologic therapy, and secukinumab as the dominant research themes, while co-citation analysis highlighted pivotal trials and treatment guidelines. Conclusion: Research on biologic therapy for HS has grown substantially reflecting the rapid evolution of targeted therapies and increasing collaboration. This bibliometric analysis provides an overview of publication trends, influential contributors, and emerging research directions.

🔖

Bu Makaleye Atıf Yap

Ünal, E., Yücel, M. B. (2026). Global research trends in biologic therapy for hidradenitis suppurativa: a bibliometric analysis. Journal of Medicine and Palliative Care, Volume: 7 Issue: 5. https://ajindex.com/articles/1668104

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (23)

  1. Nguyen TV, Damiani G, Orenstein LAV, Hamzavi I, Jemec GB. Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life. J Eur Acad Dermatol Venereol. 2021;35(1):50-61. doi:10.1111/jdv.16677
  2. Sabat R, Alavi A, Wolk K, et al. Hidradenitis suppurativa. Lancet. 2025; 405(10476):420-438. doi:10.1016/S0140-6736(24)02475-9
  3. Garg A, Kirby JS, Lavian J, Lin G, Strunk A. Sex- and age-adjusted population analysis of prevalence estimates for hidradenitis suppurativa in the United States. JAMA Dermatol. 2017;153(8):760-764. doi:10.1001/jamadermatol.2017.0201
  4. Amat-Samaranch V, Agut-Busquet E, Vilarrasa E, Puig L. New perspectives on the treatment of hidradenitis suppurativa. Ther Adv Chronic Dis. 2021;12:20406223211055920. doi:10.1177/20406223211055920
  5. Napolitano M, Megna M, Timoshchuk EA, et al. Hidradenitis suppurativa: from pathogenesis to diagnosis and treatment. Clin Cosmet Investig Dermatol. 2017;10:105-115. doi:10.2147/CCID.S111019
  6. Huang CH, Huang IH, Tai CC, Chi CC. Biologics and small molecule inhibitors for treating hidradenitis suppurativa: a systematic review and meta-analysis. Biomedicines. 2022;10(6):1303. doi:10.3390/biomedicines10061303
  7. Naik HB, Mørup MF, Davis L, et al. Short-term efficacy of biologics in moderate-to-severe hidradenitis suppurativa: a systematic review and NMA. J Eur Acad Dermatol Venereol. 2026;40(4):646-657. doi:10.1111/jdv.70265
  8. Kimball AB, Okun MM, Williams DA, et al. Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med. 2016;375(5):422-434. doi:10.1056/NEJMoa1504370
  9. Microsoft Corporation. Microsoft Excel. Version 2016. Microsoft Corporation. Accessed July 17, 2026. https://office.microsoft.com/excel
  10. RStudio team. RStudio: Integrated Development Environment for R. Posit Software, PBC; 2023. Accessed July 17, 2026. https://posit.co/
  11. Aria M, Cuccurullo C. Bibliometrix: an R-tool for comprehensive science mapping analysis. J Informetr. 2017;11(4):959-975. doi:10.1016/j.joi.2017.08.007
  12. van Eck NJ, Waltman L. Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics. 2010;84(2):523-538. doi:10.1007/s11192-009-0146-3
  13. Kimball AB, Jemec GBE, Alavi A, et al. Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials. Lancet. 2023;401(10378):747-761. doi:10.1016/S0140-6736(23)00022-3
  14. Tzanetakou V, Kanni T, Giatrakou S, et al. Safety and efficacy of anakinra in severe hidradenitis suppurativa: a randomized clinical trial. JAMA Dermatol. 2016;152(1):52-59. doi:10.1001/jamadermatol.2015.3903
  15. Zouboulis CC, Desai N, Emtestam L, et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol. 2015;29(4):619-644. doi:10.1111/jdv.12966
  16. Kimball AB, Sobell JM, Zouboulis CC, et al. HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study. J Eur Acad Dermatol Venereol. 2016;30(6):989-994. doi:10.1111/jdv.13216
  17. Zouboulis CC, Tzellos T, Kyrgidis A, et al. Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity. Br J Dermatol. 2017;177(5):1401-1409. doi:10.1111/bjd.15748
  18. Charrow A, Santiago-Soltero K, Porter M. Biologics in hidradenitis suppurativa: progress and new directions. J Am Acad Dermatol. 2024; 91(6S):S27-S30. doi:10.1016/j.jaad.2024.09.027
  19. Kimball AB, Jemec GBE, Sayed CJ, et al. Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials. Lancet. 2024;403(10443):2504-2519. doi:10.1016/S0140-6736(24)00101-6
  20. Mendes-Bastos P, Benhadou F, Venturini M, et al. Biologic drugs in hidradenitis suppurativa: what does the GP have to know? A narrative review. Front Med (Lausanne). 2024;11:1403455. doi:10.3389/fmed.2024.1403455
  21. Zouboulis CC, Bechara FG, Benhadou F, et al. European S2k guidelines for hidradenitis suppurativa/acne inversa part 2: treatment. J Eur Acad Dermatol Venereol. 2025;39(5):899-941. doi:10.1111/jdv.20472
  22. Alikhan A, Sayed C, Alavi A, et al. North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations: part II: topical, intralesional, and systemic medical management. J Am Acad Dermatol. 2019;81(1):91-101. doi:10.1016/j.jaad.2019.02.068
  23. Martora F, Tommasino N, Esposito V, Brescia C, Megna M. Hidradenitis suppurativa and IL-17 inhibitors: a focus on trials and real-life data. Medicina (Kaunas). 2026;62(5):952. doi:10.3390/medicina62050952